血浆置换联合连续性血浆透析滤过治疗慢加急性肝衰竭患者临床疗效及其对血浆细胞因子水平的影响

doi:10.3969/j.issn.1672-5069.2019.04.023

摘要/Abstract

摘要： 目的研究使用连续性血浆透析滤过（CPDF）和血浆置换（PE）治疗慢加急性肝衰竭（ACLF）患者的临床疗效及其对血浆细胞因子水平的影响。方法 2012年3月~2017年4月西京医院收治的ACLF患者92例,其中46例接受常规护肝和支持治疗,另46例观察组在常规治疗的基础上联合使用CPDF和PE治疗。采用ELISA法检测血清细胞因子水平,采用脂多糖法测定血清内毒素水平,使用L-8800氨基酸自动检测仪测定血清芳香族和支链氨基酸水平。结果在治疗后,观察组血清凝血酶原时间国际标准化比值（INR）和总胆红素（TBIL）水平显著低于,而血清白蛋白（ALB）水平显著高于对照组（P<0.05）;观察组血清肿瘤坏死因子（TNF-α）、白介素（IL）-6和IL-8水平显著低于对照组[分别为（68.9±43.3） pg/ml对（89.7±39.5） pg/ml、（53.3±39.7） pg/ml 对（69.4±41.2） pg/ml和（271.7±135.4） pg/ml 对（307.6±147.2） pg/ml,P<0.05];观察组血清内毒素水平为0.2（0.2,0.4） EU/ml,显著低于对照组【1.1（0.8,1.7） EU/mL,P<0.05】,血氨水平为（64.8±19.4） μg/L,显著低于对照组【（80.3±31.1） μg/L,P<0.05】,芳香氨基酸水平为2.1（1.5,2.7） mg/dL,显著低于对照组【（2.3（1.8,2.5） mg/dL,P<0.05】,而支链氨基酸水平为（2.6±0.5）mg/dL,显著高于对照组【（2.1±0.1） mg/dL,P<0.05】;在治疗6个月末,观察组死亡15例（32.6%）,而对照组死亡20例（43.5%,P>0.05）。结论使用PE联合CPDF治疗ACLF患者能降低血清毒素和细胞因子水平,短期改善肝功能指标,但是否能提高患者生存率,还需要继续研究。

关键词: 慢加急性肝衰竭, 血浆置换, 连续性血浆透析滤过, 细胞因子, 治疗

Abstract: Objective To investigate the efficacy of plasma exchange （PE） and continuous plasma dialysis filtration （CPDF） in the treatment of patients with acute-on-chronic liver failure （ACLF）.Methods 92 patients with ACLF were recruited between March 2012 and April 2017,and 46 patients in the control was treated with routine supporting treatment and another 46 in the observation was treated with combination of PE and CPDF at the basis of conventional treatment. Serum cytokine,endotoxin,aromatic and branched-chain amino acid levels were assayed.Results After treatment,the international standardized ratio（INR） of prothrombin time and total serum bilirubin in the observation group were significantly lower than while serum albumin level were significantly higher than in the control（P<0.05）;serum tumor necrosis factor,interleukin （IL）-6 and IL-8 levels in the observation group were significantly lower than those in the control group [（68.9±43.3） pg/ml vs.（89.7±39.5） pg/ml,（53.3±39.7） pg/ml vs. （69.4±41.2） pg/ml,and （271.7±135.4） pg/ml vs. （307.6±147.2） pg/ml, P<0.05];blood endotoxin level was 0.2（0.2,0.4）EU/ml,much lower than 【1.1（0.8,1.7） EU/mL,P<0.05】,blood ammonia level was （64.8±19.4） μg/L,much lower than【（80.3±31.1） μg/L,P<0.05】,and aromatic amino acid levels was 2.1（1.5,2.7） mg/dL,much lower than 【（2.3（1.8,2.5） mg/dL,P<0.05】,while branched-chain amino acid levels was（2.6±0.5） mg/dL,much higher than【（2.1±0.1）mg/dL,P<0.05】 in the control;the fatality rates in the two groups at the end of six month treatment were not significantly different （32.6% vs. 43.5%,P>0.05）. Conclusion The application of PE and CPDF in treatment of patients with ACLF might decrease blood cytokine,endotoxin,ammonia and aromatic amino acid levels,which warrants further investigation for their clinical efficacy.

Key words: Acute-on-chronic liver failure, Plasma exchange, Continuous plasma dialysis filtration, Cytokines, Therapy

王媛, 党盼玉, 王伟. 血浆置换联合连续性血浆透析滤过治疗慢加急性肝衰竭患者临床疗效及其对血浆细胞因子水平的影响[J]. 实用肝脏病杂志, 2019, 22(4): 541-544.

Wang Yuan, Dang Panyu, Wang Wei. Application of plasma exchange and continuous plasma dialysis filtration in the treatment of patients with acute-on-chronic liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 541-544.

参考文献

[1] Schneditz D,Ribitsch W,Schilcher G et al. Concordance of absolute and relative plasma volume changes and stability of F cells in routine hemodialysis. Hemodial Int,2016,20(1):120-128.
[2] 李晨,游绍莉,辛绍杰. HBV相关ACLF前期概念及诊疗新进展. 实用肝脏病杂志,2015,18(1):105-108.
[3] Woodhouse CA,Patel VC,Singanayagam A,et al.The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther,2018,47(2):192-202.
[4] Yokoi T,Oda S,Shiga H,et al.Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure. Transfus Apher Sci,2009,40(1):61-70.
[5] Galach M,Antosiewicz S,Baczynski D,et al.Sequential peritoneal equilibration test:a new method for assessment and modelling of peritoneal transport. Nephrol Dial Transplant,2013,28(2):447-454.
[6] Botelho C,Rodrigues A,Oliveira JC,et al.Peritoneal phosphate removal varies by peritoneal dialysis regimen:an underestimated parameter of phosphate control. J Nephrol,2013,26(1):183-190.
[7] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版). 实用肝脏病杂志,2013,16(3):210-216.
[8] Mariano F,Leporati M,Carignano P,et al.Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies. J Nephrol,2015,28(5):623-631.
[9] Ichai P,Samuel D.Dynamic outcome prediction for paracetamol-related acute liver failure. Lancet Gastroenterol Hepatol,2016,1(3):177-178.
[10] Li M,Sun J,Li J,et al.Clinical observation on the treatment of acute liver failure by combined non-biological artificial liver. Exp Ther Med,2016,12(6):3873-3876.
[11] Raoufinia R,Mota A,Keyhanvar N,et al.Overview of albumin and its purification methods. Adv Pharm Bull,2016,6(4):495-507.
[12] 邓勤智,夏邦恩,王世和,等. 土茯苓组方在乙型肝炎病毒ACLF中的应用及疗效分析.中华中医药杂志,2015,30(3):739-742.
[13] Karki P,Malik S,Mallick B,et al.Massive hemolysis causing renal failure in acute hepatitis E infection. J Clin Transl Hepatol,2016,4(4):345-347.
[14] 张绪清,毛青. 急性肝衰竭早期预警及预后评估. 实用肝脏病杂志,2013,16(1):14-16.
[15] Clària J,Arroyo V,Moreau R.The acute-on-chronic liver failure syndrome,or when the innate immune system goes astray. J Immunol,2016,197(10):3755-3761.
[16] Kim SH,Song GW,Hwang S,et al.Feasibility of ABO-incompatible adult living donor liver transplantation for acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int,2017,16(6):662-664.
[17] Pannu AK,Bhalla A,Rao C,et al.Delta model for end-stage liver disease and delta clinical prognostic indicator as predictors of mortality in patients with viral acute liver failure. Int J Crit Illn Inj Sci,2017,7(4):252-255.
[18] André P,Villain F.Free radical scavenging properties of mannitol and its role as a constituent of hyaluronic acid fillers:a literature review. Int J Cosmet Sci,2017,39(4):355-360.
[19] Cheng Y,Freeden C,Zhang Y,et al.Biliary excretion of pravastatin and taurocholate in rats with bile salt export pump (Bsep) impairment. Biopharm Drug Dispos,2016,37(5):276-86.
[20] Bhatnagar G,Sharma S,Kumar A,et al.Reduced glutathione in hepatitis E infection and pregnancy outcome. J Obstet Gynaecol Res,2016,42(7):789-795.
[21] Seyam E,Hasan M,Khalifa EM,et al.Evaluation of tumor necrosis factor alpha serum level in obese and lean women with clomiphene citrate-resistant polycystic ovary disease. Gynecol Endocrinol,2017,33(11):892-898.